|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123809 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-30 09:46:12 |
|
注册时间: Date of Registration: |
2026-04-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
戊二酸利那拉生酯胶囊治疗反流性食管炎的有效性与安全性:一项多中心、前瞻性真实世界研究 |
|
Public title: |
Efficacy and Safety of Valagliflozin Proglumetac Capsules in the Treatment of Reflux Esophagitis: A Multicenter, Prospective, Real-World Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
戊二酸利那拉生酯胶囊治疗反流性食管炎的有效性与安全性:一项多中心、前瞻性真实世界研究 |
|
Scientific title: |
Efficacy and Safety of Valagliflozin Proglumetac Capsules in the Treatment of Reflux Esophagitis: A Multicenter, Prospective, Real-World Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈坛辀 |
研究负责人: |
陈坛辀 |
|
Applicant: |
Tanzhou Chen |
Study leader: |
Tanzhou Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 13706661269 |
研究负责人电话: Study leader's telephone: |
+86 577 86689192 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
cctzz@163.com |
研究负责人电子邮件: Study leader's E-mail: |
cctzz@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江省温州市瓯海区温州医科大学附属第一医院南白象院区 |
研究负责人通讯地址: |
中国浙江省温州市瓯海区温州医科大学附属第一医院南白象院区 |
|
Applicant address: |
Nanbai xiang Branch, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou, Zhejiang, China |
Study leader's address: |
Nanbai xiang Branch, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
温州医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Wenzhou Medical University |
||
|
研究负责人所在单位: |
温州医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Wenzhou Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临床研究伦审Issuing Number(2026)第(052)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
温州医科大学附属第一医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee in Clinical Research (ECCR) of the First Affiliated Hospital of Wenzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-27 00:00:00 |
||
|
伦理委员会联系人: |
黄胜威 |
||
|
Contact Name of the ethic committee: |
Shengwei Huang |
||
|
伦理委员会联系地址: |
中国浙江省温州市瓯海区温州医科大学附属第一医院南白象院区 |
||
|
Contact Address of the ethic committee: |
Nanbai xiang Branch, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 577 55578056 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
huangsw58@163.com |
|
研究实施负责(组长)单位: |
温州医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Wenzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国浙江省温州市瓯海区温州医科大学附属第一医院南白象院区 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Nanbai xiang Branch, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-Selected Topic (Self-Funded) |
||||||||||||||||||||||
|
Target disease: |
Reflux Esophagitis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
比较在真实世界临床实践中,接受戊二酸利那拉生酯胶囊治疗与接受常规治疗(除 P-CAB 外的药物)的反流性食管炎患者,治疗 8 周后的食管黏膜愈合率的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the differences in esophageal mucosal healing rate at week 8 between patients with reflux esophagitis treated with Valagliflozin Proglumetac Capsules and those receiving conventional therapy (excluding P-CABs) in real-world clinical practice. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.18 周岁≤年龄≤75 周岁,性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age >= 18 years and <=75 years, with no gender restriction. 2.Patients diagnosed with reflux esophagitis of Los Angeles (LA) Grade A to D by endoscopy. 3.Participants have been informed of all relevant requirements of the study, are willing to participate, and have provided written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.对戊二酸利那拉生酯胶囊及辅料成分过敏; 2.正在服用阿扎那韦、奈非那韦或者利匹韦林(避免药物相互作用); 3.妊娠或哺乳期女性;或育龄期女性在筛选期血/尿妊娠试验阳性;或育龄期女性在研究期间不愿使用有效避孕措施; 4.研究者判断受试者伴有严重的中枢神经系统、呼吸系统、泌尿系统、 内分泌系统或血液系统疾病等,可能混淆研究结果或影响受试者安全性或 其他不适合参加试验的情况; 5. 严重肝肾功能不全的患者,其定义为:Child-Pugh 分级 B/C 级的肝硬化、肝功能实验室指标显著异常(如 ALT/AST > 3 倍正常值上限,INR > 1.5),或肾小球滤过率 < 30 mL/min/1.73 m^2的终末期肾病患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Hypersensitivity to valagliflozin proglumetac or any of its excipients; 2.Current use of atazanavir, nelfinavir, or rilpivirine (to avoid drug-drug interactions); 3.Pregnant or lactating female; or female of childbearing potential with a positive blood/urine pregnancy test during the screening period; or female of childbearing potential unwilling to use effective contraceptive measures during the study; 4.Subjects judged by the investigator to have severe disorders of the central nervous system, respiratory system, urinary system, endocrine system, or hematological system, which may confound study results, compromise subject safety, or constitute other conditions inappropriate for trial participation. 5.Patients with severe hepatic and renal insufficiency, defined as: liver cirrhosis of Child-Pugh Class B/C, markedly abnormal liver function laboratory parameters (e.g., ALT/AST > 3 × upper limit of normal, INR > 1.5), or end-stage renal disease with an estimated glomerular filtration rate < 30 mL/min/1.73 m^2. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC采集 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC collection |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |